# Efinopegdutide

Canonical source: https://retacompare.com/encyclopedia/efinopegdutide

Once-weekly dual GLP-1 / glucagon receptor agonist optimized for liver fat reduction.

Reference facts

Also known asMK-6024, JNJ-64565111, HM12525ACategoryGLP-1 & MetabolicMechanism of actionOnce-weekly dual GLP-1 / glucagon receptor agonist optimized for liver fat reduction.TargetsGLP-1R, GCGRIndications under research or approvedMASH, ObesityRegulatory status (reference entry)Investigational (Phase 2)Half-life~6–8 daysSequenceHSQGTFTSDYSKYLDEKAAKEFIEWLLEGGPSSGAPPPSSequence notesDual GLP-1 / glucagon agonist on Hanmi's LAPSCOVERY half-life extension platform (PEGylated Fc-like carrier).Molecular weight (Da)60000Originator / sponsorMerck (license from Hanmi)First reported2018
    Primary References

Efinopegdutide vs Semaglutide MASH, JAMA Netw Open 2023


    Explore research articles about Efinopegdutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Efinopegdutide vs Semaglutide MASH, JAMA Netw Open 2023: https://pubmed.ncbi.nlm.nih.gov/37782488/